Section Arrow
QTTB.NASDAQ
- Q32 Bio
Quotes are at least 15-min delayed:2026/09/04 00:11 EDT
Regular Hours
Last
 12.8
-0.79 (-5.81%)
Day High 
13.59 
Prev. Close
13.59 
1-M High
16.98 
Volume 
491.58K 
Bid
12.77
Ask
13.33
Day Low
12.74 
Open
13.52 
1-M Low
13.35 
Market Cap 
404.57M 
Currency 美元 
P/E 4.33 
%Yield -- 
10-SMA 15.47 
20-SMA 15.53 
50-SMA 15 
52-W High 23.5699 
52-W Low 1.68 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.14/-1.57
Enterprise Value
412.98M
Balance Sheet
Book Value Per Share
3.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
53.74M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.